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SUMMARY
Global coverage of infant Haemophilus inﬂuenzae type b (Hib) vaccination has increased
considerably during the past decade, partly due to GAVI Alliance donations of the vaccine to
low-income countries. In settings where large numbers of children receive only one or two vaccine
doses rather than the recommended three doses, dose-speciﬁc eﬃcacy estimates are needed to
predict impact. The objective of this meta-analysis is to determine Hib vaccine eﬃcacy against
diﬀerent clinical outcomes after receiving one, two or three doses of vaccine. Studies were eligible
for inclusion if a prospective, controlled design had been used to evaluate commercially available
Hib conjugate vaccines. Eight studies were included. Pooled vaccine eﬃcacies against invasive
Hib disease after one, two or three doses of vaccine were 59%, 92% and 93%, respectively. The
meta-analysis provides robust estimates for use in decision-analytical models designed to predict
the impact of Hib vaccine.
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INTRODUCTION
Haemophilus inﬂuenzae type b (Hib) is an encap-
sulated, Gram-negative coccobacillus that can cause
childhood meningitis, pneumonia and a number of
rarer forms of disease, such as epiglottitis, septicaemia
and cellulitis [1]. Hib conjugate vaccines have gradu-
ally been introduced into more and more routine
programmes since the early 1990s. While 89 countries
used the vaccine in 2004, the number had increased to
172 countries by 2011 [2]. In low- and lower-middle-
income countries, introduction of the vaccine has to a
large extent been facilitated by support from the
GAVI Alliance [3].
The ﬁrst Hib vaccine was produced in the early
1970s and composed of puriﬁed Hib capsular poly-
saccharide. However, since this vaccine was only ef-
fective in children aged >2 years it was not widely
used [4]. More immunogenic vaccines were developed
in the late 1980s by conjugating capsular poly-
saccharides to protein carriers. Four diﬀerent Hib
conjugate vaccines have been developed, diverging in
the carrier protein, the method of conjugation, and
in the structure and lengths of the polysaccharide
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polyribosolribitol phosphate (PRP) element [4]. The
four vaccine types are known as PRP-D, PRP-OMP,
HbOC and PRP-T. The PRP-D vaccine was licensed
following a randomized controlled trial (RCT) in
Finnish children [5], but when it subsequently proved
ineﬀective in preventing Hib disease in Alaskan na-
tives [6], production was stopped. Hence, today only
the other three vaccines are in use. While the World
Health Organization does not diﬀerentiate between
the three vaccines [7], they are not identical ; for ex-
ample, PRP-OMP induces a substantial antibody re-
sponse after a single dose while PRP-T and HbOC
require two doses [8].
Vaccine eﬃcacy is measured in RCTs with the
aim of determining whether infection is reduced
under ideal conditions designed to maximize disease
detection [9]. The objective of this meta-analysis is
to determine dose-speciﬁc eﬃcacy of commercially
available Hib vaccines against diﬀerent clinical out-
comes. These estimates are important parameter va-
lues when modelling the impact and cost-eﬀectiveness
of Hib vaccine [10]. In simple models, the vaccine-
preventable disease burden is estimated as:
disease
incidence
r vaccine
coverage (3 doses)
r vaccine
efficacy (3 doses)
:
While such estimates will clearly exclude the potential
indirect ‘herd immunity’ beneﬁts for unvaccinated
children, they will also underestimate the direct im-
pact attributed to partially vaccinated children. In
low- and lower-middle-income settings with weak
health systems, many children receive only one or two
vaccine doses rather than the recommended three.
Since vaccine eﬃcacy will be lower in these partially
vaccinated children, dose-speciﬁc estimates of vaccine
eﬃcacy are required to improve estimates of expected
vaccine impact. If possible, other factors, such as late
vaccination, should also be incorporated into esti-
mates of the direct eﬀect of a vaccination programme
[11]. Moreover, with more new vaccines being intro-
duced, such as pneumococcal and rotavirus vaccines,
the routine vaccination schedule is being questioned
with regard to the appropriate age and timing of
vaccination [12]. Pooled dose-speciﬁc eﬃcacy esti-
mates from all RCTs are a crucial piece of infor-
mation needed to guide these considerations.
One other meta-analysis of Hib vaccine RCTs was
identiﬁed before the present review was started.
Obonyo & Lau searched the literature until 2005
and included eight studies, two of which were of the
PRP-D vaccine [13]. The pooled eﬃcacy estimate
against invasive Hib disease was found to be 84%
[95% conﬁdence interval (CI) 70–99]. As is common
in the reporting of vaccine trial results, few dose-spe-
ciﬁc values were presented.
Vaccine eﬀectiveness studies are designed to
measure protectiveness under ﬁeld conditions. These
can either be a prospective cohort study, a case-
control study, or data can be accumulated retro-
spectively from routine surveillance. For establishing
Hib vaccine eﬀectiveness the case-control method,
where a group of cases with the target outcome, most
frequently Hib meningitis, is contrasted with a group
of controls who did not develop the target outcome, is
the most commonly used method [14]. An important
challenge of case-control studies is, however, to pro-
duce convincing evidence that the vaccinated and
unvaccinated populations are suﬃciently alike in all
relevant characteristics other than vaccination to
allow a reasonable conclusion that the diﬀerences
between groups are attributable to vaccine eﬃcacy.
A meta-analysis of Hib vaccine eﬀectiveness studies
was published by O’Loughlin et al. in 2010 [14].
Twenty-ﬁve studies, of which 14 were case-control
studies, were identiﬁed. Three of the studies reported
vaccine eﬀectiveness against invasive Hib disease after
three doses and the pooled estimate was 95% (95%
CI 82–99). One of the conclusions from this review
was that the eﬀectiveness of Hib vaccine has been
well documented and the need for more case-control
studies is minimal [14].
Search strategy and study selection
Recommendations of the Preferred Reporting Items
for Systematic Reviews andMeta-Analyses (PRISMA)
statement were used [15]. Studies were identiﬁed from
the Cochrane Controlled Trials Register (CCTR)
using the search term ‘haemophilus vaccine’ in March
2011. The CCTR is a bibliographical database of
controlled trials systematically identiﬁed from Med-
line and EMBASE by contributors of the Cochrane
Collaboration [16]. Reference lists in identiﬁed papers
were checked and experts in the ﬁeld were contacted
to conﬁrm that no studies had been missed.
Studies were eligible for inclusion if they compared
a commercially available Hib vaccine with placebo, if
clinical endpoints were reported, and if participants
had been allocated prospectively using random or
quasi-random allocation. To maximize the amount of
data available, quality measures were not used as ex-
clusion criteria. There were no language restrictions.
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Data extraction and quality assessment were per-
formed by two authors independently (U.K.G. and
A.C.). Extracted data included setting, type of Hib
vaccine, schedule, dosage, duration, number of Hib
disease cases according to study group, and total
numbers of children in both groups. Cochrane’s Risk
of Bias tool was used to assess the methodological
quality of the trials [17].
Outcome measures
In most epidemiological studies of Hib disease, focus
is solely placed on invasive disease, deﬁned as the
isolation of Hib from a sterile site such as the blood-
stream, synovial ﬂuid or cerebrospinal ﬂuid. Non-
invasive disease occurs when Hib has been isolated
from a non-sterile site, such as an external ear or
throat swab. All severe types of Hib diseases, such as
pneumonia, meningitis, epiglottitis and sepsis, are in-
vasive. However, the aetiology of invasive pneumonia
is intrinsically diﬃcult to determine [18]. The only
method which would reliably determine the aetiology
is culture of lung aspirate, but this procedure is
invasive and not ethically feasible in all RCTs.
Moreover, selection bias will occur if antibiotics are
commonly used before seeking healthcare as this will
markedly reduce the sensitivity of the lung aspirate
test [19]. Blood culture is only useful when pneumonia
is associated with bacteraemia, which is only in a
fraction of cases. The yield from blood culture in
patients with Hib pneumonia has ranged from 10%
to 30% [20, 21]. Hence, since there are currently no
validated and speciﬁc methods for conﬁrming the
pathogen-speciﬁc bacterial aetiology of pneumonia,
several non-speciﬁc pneumonia endpoints have been
used in Hib vaccine RCTs.
The following outcomes were included in the meta-
analysis : (i) conﬁrmed invasive Hib disease, (ii) con-
ﬁrmed Hib meningitis, (iii) conﬁrmed Hib pneu-
monia, (iv) clinical meningitis, (v) radiologically (or
chest X-ray) conﬁrmed pneumonia, (vi) hospitalized
pneumonia and (vii) clinical pneumonia. In addition,
eﬃcacy estimates were calculated according to the
number of doses of Hib vaccine received as either (i)
only one dose, (ii) only two doses or (iii) three doses.
Statistical analysis
All statistical analyses were performed with Stata
version 11 (StataCorp., USA). Trial results were ex-
pressed as percent vaccine eﬃcacy, deﬁned as 1 –
relative risk. Estimates were pooled using a random-
eﬀects model applying the DerSimonian & Laird
approach [22]. Heterogeneity was assessed using the
x2 test with a P value of <0.10 indicating statistical
signiﬁcance and by the I2 statistic, which measures the
percentage of variation attributable to heterogeneity.
A value of 0% indicates no observed heterogeneity
and larger values show increasing heterogeneity [23].
RESULTS
Characteristics of eligible trials
The search strategy yielded 493 references (Fig. 1).
After removing duplicates, 474 titles and abstracts
were screened and 459 papers excluded. The most
common reason for exclusion at this stage was that
the study reported only safety and immunogenicity of
the vaccine with no clinical endpoints. Fifteen papers
were retrieved for full-text review and seven of these
were excluded. One of the excluded studies was a
493 articles identified from 
Cochrane Clinical Trial Registry
474 articles screened after 
duplicates removed 
459 articles excluded
- 268 no clinical endpoints
- 147 not Hib
- 17 adult vaccination
- 13 polysaccharide vaccine
- 12 reviews
- 2 PRP-D vaccine trials
15 articles assessed for 
eligibility 
7 articles excluded
- 1 letter
- 1 carriage study
- 1 PRP-D vaccine trial
- 1 descriptive study
- 2 case-control studies
- 1 HBoC study without a 
prospective control group
8 articles included in 
meta-analysis
Fig. 1. Study selection.
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large, Finnish prospective study where children
born on even-numbered days received HbOC vaccine
and those born on uneven-numbered days received
PRP-D vaccine [24]. Vaccine eﬃcacy was estimated
by comparing the number of Hib disease cases during
the study period with the number expected based on
historical routine surveillance data. The study was
excluded because the comparison group was histori-
cal, not prospective.
Six of the eight included papers evaluated PRP-T,
one HbOC and one PRP-OMP vaccines (see Table 1).
The studies by Lagos and Levine analysed the same
trial participants. Three of the studies were from the
USA and the remaining from England, Chile, The
Gambia and Indonesia. One of the US studies was
conducted in a Navajo Indian reservation, targeting a
group with one of the highest incidences of Hib dis-
ease in the world [25]. In this trial only two doses of
Hib vaccine were administered, while three doses were
evaluated in the seven remaining studies. The study by
Vadheim ended prematurely due to inclusion of the
HbOC vaccine in the US routine vaccination schedule
while the study was ongoing, so no vaccine eﬃcacy
estimates were reported because the sample sizes were
too small to achieve suﬃcient power. In all the stud-
ies, follow-up stopped after a speciﬁed time period.
The study by Booy had the shortest follow-up time
and the study by Mulholland the longest, with the
oldest children being aged 18 and 30 months, re-
spectively, when the studies ended (Table 1).
Outcome measures used in the trials are summar-
ized in Table 2. The outcome measure used by most of
the studies was invasive Hib disease. While all types of
Hib diseases are included within the invasive disease
group, meningitis is likely to be the most frequent type
of syndrome detected. In the study by Gessner, the
only outcome measure that included aetiological
conﬁrmation was Hib meningitis. The studies by
Booy, Levine and Vadheim did not report vaccine
eﬃcacy for less than three vaccine doses.
Clinical, non-speciﬁc pneumonia outcomes were
included in the RCTs from Chile, The Gambia and
Indonesia. Since pneumonia disease incidence is con-
siderably less in high-income than low-income coun-
tries, non-speciﬁc pneumonia endpoints were not
relevant to include in the RCTs from England and the
USA. However, in low-income countries prevention
of pneumonia may be the primary argument for in-
troducing Hib vaccine, so it was crucial for the studies
in these countries to measure eﬃcacy against pneu-
monia.T
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Methodological quality of trials and risk of bias
The domains speciﬁed in Cochrane’s Risk of Bias tool
are summarized in Table 3. Risks of bias due to ran-
domization, sequence generation and allocation con-
cealment were relatively low in all the studies. Even
though two studies were not randomized, it seems
unlikely that the results would be biased for this
reason. However, four of the studies were not blinded
and this leads to risk of bias. In the three studies
where conﬁrmed Hib disease was the only endpoint,
the risk of bias would most likely be low because the
microbiologists undertaking the tests for Hib were not
aware of the child’s vaccination status. However, in
the Levine study, radiological and hospitalized pneu-
monia were the chosen endpoints and assessments of
these were made from hospital records of children
with known vaccination status, leading to moderate
risk of bias. With regard to inclusion of all random-
ized participants, all the studies suﬀer from high risk
of bias due to the inherent diﬃculties of diagnosing
Hib. Even in the studies with enhanced surveillance, it
is possible that not all Hib cases were detected. The
risk of detection bias is especially large in the three
studies with non-speciﬁc (or all-cause) pneumonia as
an outcome.
An additional risk of bias in the studies using
non-speciﬁc pneumonia outcomes is that estimated
Hib vaccine eﬃcacy will vary with the relative pro-
portion of Hib pneumonia occurring during the study
period. Since many of the other pathogens that cause
pneumonia are known to be seasonal, such as for in-
stance respiratory synical virus (RSV) or inﬂuenza,
this could be a problem. Hib vaccine eﬃcacy against
clinical pneumonia would for instance be less in a
year with a RSV pneumonia outbreak than in a year
with low RSV incidence [26]. Since all the trials
lasted for more than one year, seasonal ﬂuctuations
might have been evened out to some extent, but
the risk of this bias is apparent. This is also an im-
portant limitation to bear in mind when general-
izing the eﬃcacy values to other settings where
the relative proportion of Hib pneumonia may be
diﬀerent.
The risk of publication bias is considered low for
vaccine trials. Since these are large trials involving
thousands of children and lasting several years, there
is strong pressure on investigators and vaccine manu-
facturers to publish the results. It is thus highly un-
likely that any Hib vaccine RCTs have taken place
without being published.T
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Table 3. Assessment of risk of bias in the included trials
First author
(ref.)
Unit of
randomization Sequence generation Blinding Allocation concealment Outcome reporting
Black [41] Individual Placebo group was
refusers and children
born on the ﬁrst
5 days of a month
No, but microbiologists
performing tests for Hib
were unaware of
vaccination status
n.a. Enhanced surveillance to detect
all Hib patients treated in
the study area
Booy [42] Cluster Hib vaccine districts
determined from
availability of
computer systems
No, but microbiologists
performing tests for Hib
were unaware of
vaccination status
n.a. Enhanced surveillance to detect
all Hib patients treated in
the study area
Gessner [27] Cluster Random Double blinding Vaccine vials identical
except four colour codes;
two for Hib and two for placebo.
Code in a locked vault
Education for diagnosis and
referral. Young women in every
village to identify children with
pneumonia and get them to hospital.
Families reimbursed costs
Lagos [43] Cluster Random No, but microbiologists
performing tests for Hib
were unaware of
vaccination status
n.a. Active surveillance at 11 hospitals
in Santiago. Bacteriology laboratory
reports reviewed weekly
Levine [44] Cluster Random No n.a. Retrospective review of ﬁve
ICD-9 pneumonia
discharge diagnoses
Mulholland [21] Individual Random Double blinding Five vaccine vial codes used
for Hib and ﬁve others for
placebo. Only safety monitoring
group knew the code
Study children presenting to
health centres due to any illness
referred to study physician
Santosham [25] Cluster Random Double blinding Vaccine and placebo vials had
similar appearances. Code not
known until end of study
Active and passive
surveillance throughout
study area
Vadheim [45] Individual Random Double blinding No details given on method used Active and passive surveillance
throughout study area
n.a., Not available.
1
3
4
8
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Vaccine eﬃcacy
The pooled eﬃcacy estimates against conﬁrmed, in-
vasive Hib disease following three, two and one dose
are 93% (95% CI 83–97), 92% (95% CI 69–98) and
59% (95% CIx20 to 86), respectively (Fig. 2). There
is no heterogeneity in the studies for three and two
doses and only low heterogeneity for one dose
(I2=28.5%), which is attributable to the Santosham
study of the PRP-OMP vaccine reporting consider-
ably higher eﬃcacy than the two other studies.
The pooled one-dose estimate of the trials using
the PRP-T and the HbOC vaccines, respectively, is
47% (95% CI x28 to 70) with no heterogeneity
(I2=0.0%). The children in the vaccine groups who
experienced Hib disease after one or two doses re-
mained incompletely immunized during the course of
the studies. Hence, the cases did not occur during the
inter-vaccination intervals.
For conﬁrmed Hib meningitis there is no hetero-
geneity in any of the dose-speciﬁc estimates, but due
to the relatively small sample sizes, the conﬁdence in-
tervals are wide for one and two doses (Fig. 3).
Moreover, since the Santosham trial only estimated
one- and two-dose eﬃcacy, the pooled value for three
doses (88%, 95% CI 46–97) is less than for two doses
(92%, 95% CI 37–99). The pooled one-dose estimate
is 62% (95% CIx29 to 89).
Data on conﬁrmed Hib pneumonia were only
available from the Mulholland and Santosham stu-
dies, and Santosham did not identify any cases fol-
lowing two doses. The Mulholland midpoint eﬃcacy
estimates of both two and three doses were 91%
(95% CIx66 to 99) and the pooled estimate between
Mulholland and Santosham following one dose was
67% (95% CIx44 to 93).
Vaccine eﬃcacy against radiological pneumonia
with three doses was 22% in both the Levine and
Mulholland studies, but the result was negative in the
study by Gessner, causing large heterogeneity
(I2=68.9%) (Fig. 4). Hence, the pooled estimate has
limited validity. The pooled estimate without the
Gessner study was 22% (95% CI 6–35) with no het-
erogeneity (I2=0.0%).
Hib vaccine eﬃcacy against hospitalized pneu-
monia following three doses of vaccine was reported
by Gessner and Levine (Fig. 4). There is, however,
also large heterogeneity between these two studies
and the pooled estimate is not meaningful. While
Levine found a vaccine eﬃcacy of 26% (95% CI
7–41), Gessner only estimated it as 2% (95% CIx8
to 10).
Clinical pneumonia eﬃcacy after three doses was
reported by Gessner and Mulholland and found to
be 4% (95% CI 1–7) in both studies (Fig. 4).
However, due to the larger number of cases detected
Three doses
Black [41]
Booy [42]
Lagos [43]
Mulholland [21]
Vadheim  [45]
Subtotal  (I 2 = 0·0%, p = 0·970)
Two doses only
Black [41]
Mulholland [21]
Santosham [25]
Subtotal  (I 2 = 0·0%, p = 0·972)
One dose only
Black [41]
Mulholland [21]
Santosham [25]
Subtotal  (I 2 = 28·5%, p = 0·247)
Author
USA
UK
Chile
Gambia
USA
USA
Gambia
USA
USA
Gambia
USA
Country
HBoC
PRP-T
PRP-T
PRP-T
PRP-T
HBoC
PRP-T
PRP-OMP
HBoC
PRP-T
PRP-OMP
Type
of Hib
vaccine
12/21232
18/13320
25/36741
19/17919
3/5106
77/94318
6/4724
10/2349
14/2105
30/9178
4/4968
9/1098
8/505
21/6571
Events,
control
10·30
20·30
39·68
20·35
9·37
100·00
20·12
39·41
40·47
100·00
35·36
51·95
12·69
100·00
%
Weight
96 (31 to 100)
94 (58 to 99)
92 (65 to 98)
95 (60 to 99)
86 (–171 to 99)
93 (83 to 97)
92 (–38 to 100)
90 (20 to 99)
93 (44 to 99)
92 (69 to 98)
24 (–238 to 83)
56 (–30 to 85)
94 (3 to 100)
59 (–20 to 86)
Vaccine
efficacy (%)
0·04 (0·00–0·69)
0·06 (0·01–0·42)
0·08 (0·02–0·35)
0·05 (0·01–0·40)
0·14 (0·01–2·71)
0·07 (0·03–0·17)
0·08 (0·00–1·38)
0·10 (0·01–0·80)
0·07 (0·01–0·56)
0·08 (0·02–0·31)
0·76 (0·17–3·38)
0·44 (0·15–1·30)
0·06 (0·00–0·97)
0·41 (0·14–1·20)
RR (95% CI)
0/20800
1/13320
2/35264
1/17794
0/5211
4/92389
0/4681
1/2299
1/2056
2/9036
3/4919
5/1397
0/532
8/6848
Events,
vaccine
Favours vaccine
10·001 10
Fig. 2. Hib vaccine eﬃcacy against conﬁrmed invasive Hib disease.
The eﬃcacy of Hib vaccine : a systematic review 1349
in Indonesia compared to The Gambia, the weight of
the Gessner study in the pooled estimate is as high as
92.3%.
Clinical meningitis was only included in the study
by Gessner and three diﬀerent types were included;
probable, possible and hospitalized meningitis
(Table 4). There were consistently less cases in the
vaccinated compared to the placebo group and two of
the eﬃcacy estimates were signiﬁcant at the 95% le-
vel. This indicated that, in the Indonesian environ-
ment, many cases of Hib meningitis were reaching a
health facility, but either did not have a lumbar
puncture or lumbar puncture was done and found to
have the microscopic appearance of meningitis, but
for reasons of specimen handling or microbiological
procedures, Hib was not cultured.
Three doses
Gessner [27]
Mulholland [21]
Subtotal  (I 2 = 0·0%, p = 0·584)
Two doses only
Mulholland [21]
Santosham [25]
Subtotal  (I 2 = 0·0%, p = 0·759)
One dose only
Gessner [27]
Mulholland [21]
Santosham [25]
Subtotal  (I 2 = 0·0%, p = 0·479)
Author
Indonesia
Gambia
Gambia
USA
Indonesia
Gambia
USA
Country
PRP-T
PRP-T
PRP-T
PRP-OMP
PRP-T
PRP-T
PRP-OMP
Type
of Hib
vaccine
5/19150
12/17919
17/37069
4/2349
8/2105
12/4454
1/3815
4/1089
5/497
10/5401
Events,
control
47·44
52·56
100·00
48·79
51·21
100·00
14·69
67·33
17·98
100·00
%
Weight 
81 (–63 to 98)
92 (35 to 99)
88 (46 to 97)
89 (–111 to 99)
94 (–4 to 100)
92 (37 to 99)
68 (–683 to 99)
42 (–161 to 87)
92 (–53 to 100)
62 (–29 to 89)
Vaccine
efficacy (%)
0·19 (0·02–1·63)
0·08 (0·01–0·65)
0·12 (0·03–0·54)
0·11 (0·01–2·11)
0·06 (0·00–1·04)
0·08 (0·01–0·63)
0·32 (0·01–7·83)
0·58 (0·13–2·61)
0·08 (0·00–1·53)
0·38 (0·11–1·29)
RR (95% CI)
1/20156
1/17794
2/37950
0/2299
0/2056
0/4355
0/3988
3/1397
0/532
3/5917
Events,
vaccine
Favours vaccine
10·001 10
Fig. 3. Hib vaccine eﬃcacy against conﬁrmed Hib meningitis.
Hospitalised
Gessner [27]
Levine [44]
Subtotal  (I 2 = 80·6%, p = 0·023)
Radiological
Gessner [27]
Levine [44]
Mulholland [21]
Subtotal  (I 2 = 68·4%, p = 0·042)
Clinical
Gessner [27]
Mulholland [21]
Subtotal  (I 2 = 0·0%, p = 0·946)
Author
Indonesia
Chile
Indonesia
Chile
Gambia
Indonesia
Gambia
Country
893/18916
163/10274
1056/29190
191/19104
85/10274
170/17919
446/47297
4870/17748
570/18489
5440/36237
Events,
control
57·12
42·88
100·00
37·83
27·41
34·75
100·00
92·26
7·74
100·00
%
Weight
2 (–8 to 10)
26 (7 to 41)
13 (–15 to 34)
–10 (–33 to 9)
22 (–7 to 43)
22 (2 to 38)
11 (–14 to 30)
4 (0 to 7)
4 (–8 to 15)
4 (1 to 7)
Vaccine
efficacy (%)
0·98 (0·90–1·08)
0·74 (0·59–0·93)
0·87 (0·66–1·15)
1·10 (0·91–1·33)
0·78 (0·57–1·07)
0·78 (0·62–0·98)
0·89 (0·70–1·14)
0·96 (0·93–1·00)
0·96 (0·85–1·08)
0·96 (0·93–0·99)
RR (95% CI)
926/19934
131/11146
1057/31080
221/20102
72/11146
132/17794
425/49042
4957/18762
526/17794
5483/36556
Events,
vaccine
Favours vaccine
10·01 10
Fig. 4. Hib vaccine eﬃcacy against non-speciﬁc pneumonia outcome measures.
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DISCUSSION
All the studies demonstrated high vaccine eﬃcacy
against conﬁrmed invasive Hib disease following two
and three doses, and there was no heterogeneity in the
pooled estimate. With one dose, the pooled estimate
was 59% (95% CIx20 to 86) and there was only low
heterogeneity. Hence, the vaccine eﬃcacy evidence
against invasive disease is convincing and robust for
all dose regimens. This conclusion is similar to the
ﬁndings of O’Loughlin and colleagues in their meta-
analysis of observational studies [14]. The pooled
vaccine eﬀectiveness estimate against invasive Hib
disease from three case-control studies was 95%
(95% CI 82–99) after three doses and 92% (95% CI
81–97) following two doses. In the meta-analysis of
RCTs by Obonyo & Lau, vaccine eﬃcacy against in-
vasive Hib disease after three doses was only 84%
(95% CI 69–92). The reason for the higher pooled
estimate in the new analysis is partly the exclusion of
the PRP-D trials, but also that Obonyo & Lau com-
bined all doses into one analysis, so that children re-
ceiving only one dose, only two doses and all three
doses were included in the same estimate.
The evidence for conﬁrmed Hib meningitis and
conﬁrmed Hib pneumonia is less robust because few
studies report on these, so the pooled estimates are
based on small sample sizes, which give wide conﬁ-
dence intervals. As both diseases are contained within
the overall group of invasive Hib disease, these eﬃ-
cacy estimates should be used instead of seeking to
categorize according to invasive Hib disease type.
As expected, the strength of the evidence of vaccine
eﬃcacy against the three, non-speciﬁc pneumonia
outcomes is less than for conﬁrmed Hib disease. For
hospitalized pneumonia the heterogeneity is too large
for the eﬃcacy estimate to be meaningful. The large
heterogeneity between the Indonesian and Chilean
studies may partly be due diﬀerent case detection
methods. Pneumonia detection in Indonesia was
based on individual presentation for medical care, but
supported by village health workers whose task was
to identify children in the community with possible
severe respiratory disease and refer them for treat-
ment. By contrast, cases were retrospectively ident-
iﬁed from patient records in Chile. Another possible
explanation is diﬀerences between the two sites in the
distribution of non-Hib pneumonia aetiologies. For
example, a large burden of RSV infection in one
site will lower the measured vaccine eﬀectiveness even
if the two sites have similar vaccine-preventable
Hib disease incidences, as has been described pre-
viously [26]. Consequently, for clinical (rather than
microbiologically conﬁrmed) outcomes, vaccine-
preventable disease incidence may be a better measure
than vaccine eﬃcacy.
The Indonesian trial by Gessner did not detect an
impact on radiological pneumonia [27]. The study
authors have proposed several possible explanations
why pneumonias with lobar inﬁltrate or pleural ef-
fusion were not preventable with Hib vaccine. First,
Hib may not be an important cause of pneumonia in
Indonesia; this seems unlikely, since the vaccine-
preventable disease incidence measured against all
severe or clinical pneumonias was as high or higher
than in other studies [24]. Second, some characteristic
of children in South East Asia could lead to a diﬀerent
pneumonia presentation; this also seems unlikely
since many children presented with a lobar inﬁltrate
meeting the WHO case deﬁnition. Last, and perhaps
Table 4. Vaccine eﬃcacy against clinical meningitis in Lombok, Indonesia
Outcome measure
No. of Hib
vaccine doses
Cases/total children
Vaccine
eﬃcacy
95% CI
P valueHib Placebo Low High
Probable bacterial meningitis 1 1/3989 6/3816 84% x32 98 0.06
Probable bacterial meningitis 2 5/4006 6/3963 18% x170 75 0.77
Probable bacterial meningitis 3 9/20152 20/19147 57% 6 81 0.04*
Possible bacterial meningitis 1 3/3989 9/3819 68% x18 91 0.09
Possible bacterial meningitis 2 6/4006 6/3963 1% x206 68 1.00
Possible bacterial meningitis 3 17/20152 34/19144 53% 15 73 0.01*
Hospitalized meningitis 1 21/3993 34/3824 41% x2 66 0.06
Hospitalized meningitis 2 33/4010 41/3971 20% x26 49 0.35
Hospitalized meningitis 3 118/20144 121/19131 7% x19 28 0.56
CI, Conﬁdence interval.
* Signiﬁcant at the 95% level using Fisher’s exact t test.
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most likely, early antibiotic use through self-
medication or early intervention could have modiﬁed
the evolution of Hib pneumonia [26].
The two remaining studies by Mulholland and
Levine found a remarkably similar result of 22%
vaccine eﬃcacy against radiological pneumonia, in
spite of diﬀerent deﬁnitions used. In The Gambia,
standardized radiology readings were used while in
Chile radiology reports were searched for key words,
such as ‘alveolar consolidation’. The 22% estimate is,
however, less than in three case-control studies from
Bangladesh, Dominican Republic and Colombia,
which reported eﬀectiveness against radiological
pneumonia as 32%, 31% and 55%, respectively [14].
In a study by Theodoratou et al. [28], these three
studies were combined with the RCTs of Gessner,
Levine and Mulholland and a pooled Hib vaccine ef-
fectiveness estimate of 18% against radiological
pneumonia was generated. There was considerable
heterogeneity in the pooled estimate, but this problem
was not addressed in the study [28].
It must be emphasized that the radiological pneu-
monia outcome measure imposes a large risk of bias
due to the many deﬁnition problems of reading chest
X-rays. This was particularly illustrated in the case-
control study from Bangladesh where chest radio-
graphs were taken of 2679 children with clinical
pneumonia [29]. According to per-protocol readings,
17.7% cases were identiﬁed as having radiologically
conﬁrmed pneumonia. However, when the radio-
graphs were read by a WHO panel, it was concluded
that 26.0% were radiologically conﬁrmed, and only
13.2% of cases were radiologically conﬁrmed by both
per-protocol readings and WHO readings [29]. It is
thus diﬃcult to determine which estimate to use, and
the choice greatly aﬀects the vaccine eﬀectiveness es-
timate. When using the per-protocol readings, the
preventable fraction for radiologically conﬁrmed
pneumonia was 17% following at least two doses of
Hib vaccine. When the WHO readings were used, the
vaccine was associated with 15% protection, and
when the subset considered positive by both sets of
readings was used the vaccine oﬀered 34% protection
[29].
The pooled vaccine eﬃcacy estimate against clinical
pneumonia appears robust as there is no heterogen-
eity between the two studies. It is noteworthy that the
two studies found such comparable results as there is
a high risk of bias with this non-speciﬁc outcome
measure. However, with only two studies the evidence
is limited and as discussed earlier, the estimates
cannot be generalized to other settings without
caution due to potential ﬂuctuations in clinical pneu-
monia aetiology between countries and years.
Vaccine eﬃcacy data against non-speciﬁc outcomes
must be interpreted cautiously. While vaccine eﬃcacy
against microbiologically conﬁrmed outcomes reﬂects
the ability of the vaccine to induce protective im-
munity against infection and disease, vaccine eﬃcacy
against non-speciﬁc outcomes reﬂects vaccine per-
formance in combination with the epidemiological
context in which the vaccine is used. For example,
vaccine eﬃcacy may change by number of doses based
on a diﬀerent distribution of aetiologies at diﬀerent
immunization ages.
The PRP-T and the HbOC vaccines showed similar
dose-speciﬁc eﬃcacy values, but the PRP-OMP vac-
cine, which has diﬀerent kinetics to the other two
vaccines, had larger eﬃcacy following one dose. The
PRP-OMP vaccine has shown signiﬁcantly higher
immunogenicity after the ﬁrst dose than the two
others in all studies comparing the vaccines [8]. While
all three vaccines are indicated for primary infant
immunization, PRP-OMP may aﬀord a marginal ad-
vantage in populations with high disease burden and
carriage prevalence in young infants. For example, in
Alaska Native children – who during the pre-vaccine
era had among the highest Hib disease incidence rates
ever recorded [30] – a change from PRP-OMP to
HbOC vaccine in 1996 led to an increase in invasive
Hib disease incidence from 19.8 to 91.1 cases/100 000
children aged <5 years [31]. When the state subse-
quently switched back to PRP-OMP vaccine, disease
incidence decreased to 0/100 000 in 2004 [31].
Nevertheless, most countries in Africa have reported
a high Hib disease burden in young infants pre-
vaccine, and yet have achieved and sustained
near elimination of Hib disease with PRP-T [32], in-
dicating this vaccine is also appropriate in these
situations.
There was no signiﬁcant diﬀerence between two
and three doses, with eﬃcacy against invasive Hib
disease being 92% and 93% following two and three
doses, respectively. In theory, then, the routine
schedule could be reduced to two instead of three
doses. A study evaluating this option found that while
PRP-T elicited high immune response after two doses,
this was not universally true of PRP-HbOC, with
only 87% of infants reaching seroprotective con-
centrations [33]. The authors concluded that before
switching to a two-dose regimen, additional studies
would be needed [33]. These studies have not been
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conducted, and moreover, additional barriers to a
two-dose schedule exist. First, studies would need to
conﬁrm vaccine eﬀectiveness against carriage, since
indirect protection is a critical component of overall
disease reduction and second, additional studies
would need to conﬁrm long-term immunity and pro-
tection against carriage, as well as booster responses
with a two-dose schedule. Programmatically, Hib
vaccine is now widely introduced in combination with
DTP and other vaccines with a primary three-dose
schedule, which has large advantages. For these
reasons, it is unlikely that any country would consider
a two-dose primary series without a booster. How-
ever, if countries were to switch to a 2+1 schedule for
pneumococcal vaccines, our analysis supports the use
of the same schedule for Hib vaccine.
While not evaluated in this study, choices of vac-
cine formulations and schedules must also consider
the immune status of the population, particularly the
eﬀects of human immunodeﬁciency virus (HIV) in-
fection and malnutrition. For example, HIV infection
leads to decreased immunogenicity [34] ; however,
population impact against Hib disease in HIV-
endemic areas has varied with South Africa showing
reduced impact [35] and Malawi showing high impact
[36].
Waning immunity and the possible need for a
booster dose is another important issue to consider.
Since the medium follow-up time of the studies was
only 24 months, they do not provide evidence re-
garding the long-term protection of the vaccine.
While all high-income and some middle-income
countries recommend a Hib vaccine booster dose at
12–15 months, this has not been included in im-
munization schedules in low-income countries. The
reason for not including a booster dose is partly due
to the increased cost, which is not aﬀordable, but also
because the average age of Hib infection is substan-
tially lower in low-income compared to high-income
countries [37]. It is, however, extremely important to
closely monitor the impact of Hib vaccine in low-
income countries to establish whether a booster dose
is also needed in these settings. In South Africa an
increase in invasive Hib disease cases was observed
several years after a three-dose primary vaccination
schedule was commenced. Surveillance data showed
that about 60% of Hib vaccine failures were in HIV-
negative children and 55% occurred in children aged
>18 months; an age group that may beneﬁt directly
from a booster dose. In 2010 South African children
began receiving a Hib booster [38].
Boosting is important in sustaining both direct
protection and indirect eﬀects through reduction in
carriage. Although we could not evaluate the eﬀect of
diﬀerent schedules on carriage, this issue is of primary
importance, since much of the overall protection
against disease aﬀorded by Hib vaccination pro-
grammes derives from indirect eﬀects. In the UK, an
increase in vaccine failure 8 years after routine vacci-
nation commenced in 1999 was at least partly because
of a greater than expected decline in Hib antibody
response following a schedule without a booster in the
second year of life, which had been masked by the
initial vaccination catch-up programme of all children
aged <5 years in 1992 [39]. Moreover, the loss of
protection against Hib disease in children resulted in a
signiﬁcant increase in adult disease, probably because
reduced carriage and transmission in young children
had diminished opportunities for natural boosting of
immunity in adults, who had very low Hib antibody
levels [40]. This suggests that control of carriage and
disease in young children has important impact in
older children and adults.
Investigators of large-scale vaccination trials do
not routinely report dose-speciﬁc outcomes despite
their potential importance for the impact and cost-
eﬀectiveness of immunization programmes. Estimates
of dose-speciﬁc vaccine eﬃcacy provide a direct way
for analysts and decision makers to account for vac-
cine impact in partially vaccinated children. Models
that do not account for partial protection will under-
estimate overall programme eﬀectiveness in popu-
lations with high drop-out rates between doses.
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